Citi initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $115 price target and named it a top pick among small-to-mid cap biotech stocks. Tryngloza for severe hypertriglyceridemia leads the higher value proprietary pipeline, with a greater than $3.5B peak sales opportunity “underappreciated,” the analyst tells investors. Partnered Phase 3 readouts offer opportunities for upside momentum in the second half of 2026, the analyst added.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.